Costs of home versus inpatient treatment for fever and neutropenia: Analysis of a multicenter randomized trial

Journal of Clinical Oncology

Volumn 29, Issue 30, 2011, Pages 3984-3989

  Hendricks, Ann M ^a   Loggers, Elizabeth Trice ^c   Talcott, James A ^b  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c GROUP HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CAREGIVER; COMPARATIVE STUDY; CONTROLLED STUDY; FEBRILE NEUTROPENIA; FEMALE; HEALTH CARE COST; HOME CARE; HOSPITAL BILLING; HOSPITAL CARE; HOSPITAL CHARGE; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; MULTICENTER STUDY; PATIENT ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTI-BACTERIAL AGENTS; FEMALE; FEVER; HOME CARE SERVICES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 80054740621     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.1247     Document Type: Article

References (21)

1. Finberg RW, Talcott JA: Fever and neutropenia: How to use a new treatment strategy. N Engl J Med 341:362-363, 1999
2. Klastersky J, Paesmans M, Georgala A, et al.: Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 24:4129-4134, 2006
3. Gardembas-Pain M, Desablens B, Sensebe L, et al.: Home treatment of febrile neutropenia: An empirical oral antibiotic regimen. Ann Oncol 2:485-487, 1991
4. Rubenstein EB, Rolston K, Benjamin RS, t al: Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 71:3640-3646, 1993
5. Marti FM, Cullen MH, Roila F: Management of febrile neutropenia: ESMO clinical recommendations. Ann Oncol 20:166-169, 2009 (suppl 4)
6. Gold MR, Siegel JE, Russell LB, et al.: Cost Effectiveness in Health and Medicine. New York, NY, Oxford University Press, 1996
7. Stommel M, Given CW, Given BA: The cost of cancer home care to families. Cancer 71:1867-1874, 1993
8. Talcott JA, Yeap BY, Clark JA, et al.: Safety of early discharge for low-risk patients with febrile neutropenia: A multicenter randomized controlled trial. J Clin Oncol 29:3977-3983, 2011
9. Talcott JA, Finberg R, Mayer RJ, et al.: The medical course of cancer patients with fever and neutropenia: Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 148:2561-2568, 1988
10. Talcott JA, Siegel RD, Finberg R, et al.: Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule. J Clin Oncol 10:316-322, 1992
11. Talcott JA, Whalen A, Clark J, et al.: Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: A pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 12:107-114, 1994
12. Shwartz M, Young DW, Siegrist R: The ratio of costs to charges: How good a basis for estimating costs? Inquiry 32:476-481, 1995
13. Bash RO, Katz JA, Cash JV, et al.: Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia. Cancer 74:189-196, 1994
14. Bennett CL, Calhoun EA: Evaluating the total costs of chemotherapy-induced febrile neutropenia: Results from a pilot study with community oncology cancer patients. Oncologist 12:478-483, 2007
15. Elting LS, Lu C, Escalante CP, et al.: Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 26:606-611, 2008
16. Given BA, Given CW: Family home care for individuals with cancer. Oncology (Williston Park) 8:77-83, 1994
17. Fireman BH, Fehrenbacher L, Gruskin EP, et al.: Cost of care for patients in cancer clinical trials. J Natl Cancer Inst 92:136-142, 2000
18. Bennett CL, Golub R, Waters TM, et al.: Economic analyses of phase III cooperative cancer group clinical trials: Are they feasible? Cancer Invest 15:227-236, 1997
19. Briggs A: Economic evaluation and clinical trials: Size matters. BMJ 321:1362-1363, 2000
20. Sculpher MJ, Pang FS, Manca A, et al.: Generalisability in economic evaluation studies in healthcare: A review and case studies. Health Technol Assess 8:iii-iv, 1-192, 2004
21. Petrou S, Gray A: Economic evaluation alongside randomised controlled trials: Design, conduct, anlaysis, and reporting. BMJ 342:d1548, 2011